Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders
Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved..
Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it. We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio. The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT - 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) - 0.588*antidepressant co-prescription (yes or no) - 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11) Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable. This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology - 73(2023) vom: 31. Aug., Seite 75-81 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chouchana, Margot [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticonvulsants |
|---|
| Anmerkungen: |
Date Completed 12.03.2024 Date Revised 15.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.euroneuro.2023.04.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369553179 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369553179 | ||
| 003 | DE-627 | ||
| 005 | 20240315233546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240311s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.euroneuro.2023.04.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369553179 | ||
| 035 | |a (NLM)38465581 | ||
| 035 | |a (PII)S0924-977X(23)00073-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chouchana, Margot |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Factors associated with lamotrigine concentration/dose ratio in individuals with bipolar disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.03.2024 | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. and ECNP. All rights reserved. | ||
| 520 | |a Monitoring of lamotrigine levels is recommended in epilepsy. However, in bipolar disorders (BD), no study has described the therapeutic range in daily practice and factors being associated to it. We used retrospective data of individuals with BD, treated with lamotrigine, and included in the FondaMental Advanced Centers of Expertise for Bipolar Disorders cohort. We extracted clinical and biological data and explored associations between these variables and lamotrigine concentration/dose (C/D) ratio. The database included 675 individuals who received lamotrigine at inclusion, whose main characteristics were female sex (68.3%) and BD type 2 (52.1%). Data about lamotrigine C/D ratio were available for 205 individuals. Lamotrigine C/D ratio was significantly associated with: Body Mass Index (BMI) (r=-0.159), estimated GFR (glomerular filtration rate) (r=-0.228), total bilirubin (r = 0.241) and at a trend level, antidepressant co-prescription (U = 3169). The model obtained was: lamotrigine C/D ratio = 1.736 - 0.013*BMI + 0.095*total bilirubin (UI/L) - 0.007*eGFR (ml/min) + 0.210*AST/ALT - 0.004*GGT (UI/L) + 0.014*age (year) + 0.303*currently smoking (yes or no) - 0.588*antidepressant co-prescription (yes or no) - 0.357*gender (F = 1.899, p = 0.057, adjusted R2 = 0.11) Information about plasma lamotrigine C/D ratio were available for only 205 out of the 675 individuals in the database and has been obtained from different laboratories. The representativeness of the included sample may be questionable. This is the first study providing information on a large sample of individuals with BD regarding factors associated with lamotrigine C/D ratio. This study allows to propose a model of lamotrigine C/D ratio that would deserve further replication | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bipolar disorder | |
| 650 | 4 | |a Concentration/dose ratio | |
| 650 | 4 | |a Lamotrigine | |
| 650 | 4 | |a Plasma level | |
| 650 | 7 | |a Lamotrigine |2 NLM | |
| 650 | 7 | |a U3H27498KS |2 NLM | |
| 650 | 7 | |a Triazines |2 NLM | |
| 650 | 7 | |a Anticonvulsants |2 NLM | |
| 650 | 7 | |a Antidepressive Agents |2 NLM | |
| 650 | 7 | |a Bilirubin |2 NLM | |
| 650 | 7 | |a RFM9X3LJ49 |2 NLM | |
| 700 | 1 | |a Delage, Clément |e verfasserin |4 aut | |
| 700 | 1 | |a Godin, Ophélia |e verfasserin |4 aut | |
| 700 | 1 | |a Fontan, Jean-Eudes |e verfasserin |4 aut | |
| 700 | 1 | |a Bellivier, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Gard, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Aubin, Valérie |e verfasserin |4 aut | |
| 700 | 1 | |a Belzeaux, Raoul |e verfasserin |4 aut | |
| 700 | 1 | |a Dubertret, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Haffen, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Leboyer, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Olie, Emilie |e verfasserin |4 aut | |
| 700 | 1 | |a Courtet, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Polosan, Mircea |e verfasserin |4 aut | |
| 700 | 1 | |a Roux, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Samalin, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Schwan, Raymund |e verfasserin |4 aut | |
| 700 | 1 | |a Lefrere, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Bloch, Vanessa |e verfasserin |4 aut | |
| 700 | 1 | |a Etain, Bruno |e verfasserin |4 aut | |
| 700 | 0 | |a FondaMental Advanced Center of Expertise for Bipolar Disorders (FACE-BD) |e verfasserin |4 aut | |
| 700 | 1 | |a Etain, B |e investigator |4 oth | |
| 700 | 1 | |a Olié, E |e investigator |4 oth | |
| 700 | 1 | |a Leboyer, M |e investigator |4 oth | |
| 700 | 1 | |a Llorca, P M |e investigator |4 oth | |
| 700 | 1 | |a Barteau, V |e investigator |4 oth | |
| 700 | 1 | |a Bensalem, S |e investigator |4 oth | |
| 700 | 1 | |a Godin, O |e investigator |4 oth | |
| 700 | 1 | |a Laouamri, H |e investigator |4 oth | |
| 700 | 1 | |a Souryis, K |e investigator |4 oth | |
| 700 | 1 | |a Hotier, S |e investigator |4 oth | |
| 700 | 1 | |a Pelletier, A |e investigator |4 oth | |
| 700 | 1 | |a Bellivier, F |e investigator |4 oth | |
| 700 | 1 | |a Etain, B |e investigator |4 oth | |
| 700 | 1 | |a Hennion, V |e investigator |4 oth | |
| 700 | 1 | |a Marlinge, E |e investigator |4 oth | |
| 700 | 1 | |a Aouizerate, B |e investigator |4 oth | |
| 700 | 1 | |a Desage, A |e investigator |4 oth | |
| 700 | 1 | |a Gard, S |e investigator |4 oth | |
| 700 | 1 | |a Courtet, P |e investigator |4 oth | |
| 700 | 1 | |a Ducasse, D |e investigator |4 oth | |
| 700 | 1 | |a Molière, F |e investigator |4 oth | |
| 700 | 1 | |a Olié, E |e investigator |4 oth | |
| 700 | 1 | |a Gross, G |e investigator |4 oth | |
| 700 | 1 | |a Schwan, R |e investigator |4 oth | |
| 700 | 1 | |a Schwitzer, T |e investigator |4 oth | |
| 700 | 1 | |a Bougerol, T |e investigator |4 oth | |
| 700 | 1 | |a Pouchon, A |e investigator |4 oth | |
| 700 | 1 | |a Polosan, M |e investigator |4 oth | |
| 700 | 1 | |a Passerieux, C |e investigator |4 oth | |
| 700 | 1 | |a Roux, P |e investigator |4 oth | |
| 700 | 1 | |a Aubin, V |e investigator |4 oth | |
| 700 | 1 | |a Cussac, I |e investigator |4 oth | |
| 700 | 1 | |a Loftus, J |e investigator |4 oth | |
| 700 | 1 | |a Dubertret, C |e investigator |4 oth | |
| 700 | 1 | |a Mazer, N |e investigator |4 oth | |
| 700 | 1 | |a Llorca, P M |e investigator |4 oth | |
| 700 | 1 | |a Samalin, L |e investigator |4 oth | |
| 700 | 1 | |a Mennetrier, M |e investigator |4 oth | |
| 700 | 1 | |a Blanc, O |e investigator |4 oth | |
| 700 | 1 | |a Lacelle, D |e investigator |4 oth | |
| 700 | 1 | |a Vayssie, M |e investigator |4 oth | |
| 700 | 1 | |a Lefrere, A |e investigator |4 oth | |
| 700 | 1 | |a Moreau, E |e investigator |4 oth | |
| 700 | 1 | |a Pastol, J |e investigator |4 oth | |
| 700 | 1 | |a Murraccioli, I |e investigator |4 oth | |
| 700 | 1 | |a Suray, A |e investigator |4 oth | |
| 700 | 1 | |a Groppi, F |e investigator |4 oth | |
| 700 | 1 | |a Polomeni, H |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology |d 1997 |g 73(2023) vom: 31. Aug., Seite 75-81 |w (DE-627)NLM013028618 |x 1873-7862 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2023 |g day:31 |g month:08 |g pages:75-81 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.euroneuro.2023.04.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2023 |b 31 |c 08 |h 75-81 | ||